{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:04:56Z","timestamp":1760425496278,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["CSP-1027","Z99-AA999999","P50-AA024337-01","U01-AA021901","ZIA AA000466"],"award-info":[{"award-number":["CSP-1027","Z99-AA999999","P50-AA024337-01","U01-AA021901","ZIA AA000466"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s40261-016-0439-2","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T11:29:32Z","timestamp":1470655772000},"page":"935-944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6764-6891","authenticated-orcid":false,"given":"Vatsalya","family":"Vatsalya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie L.","family":"Schwandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew C.","family":"Cave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirish S.","family":"Barve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay A.","family":"Ramchandani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig J.","family":"McClain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,8]]},"reference":[{"issue":"3","key":"439_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1358\/dot.1999.35.3.533849","volume":"35","author":"JM Goldstein","year":"1999","unstructured":"Goldstein JM. Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barcelona, Spain: 1998). 1999;35(3):193\u2013210.","journal-title":"Drugs Today (Barcelona, Spain: 1998)"},{"issue":"7","key":"439_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/1099-1077(200010)15:7<499::AID-HUP194>3.0.CO;2-3","volume":"15","author":"M Balestrieri","year":"2000","unstructured":"Balestrieri M, Vampini C, Bellantuono C. Efficacy and safety of novel antipsychotics: a critical review. Human Psychopharmacol Clin Experim. 2000;15(7):499\u2013512.","journal-title":"Human Psychopharmacol Clin Experim."},{"issue":"10","key":"439_CR3","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S0006-3223(99)00059-1","volume":"46","author":"JM Kane","year":"1999","unstructured":"Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry. 1999;46(10):1396\u2013408.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"439_CR4","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","volume":"26","author":"ME Thase","year":"2006","unstructured":"Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR, Bolder II. Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"439_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1089\/cap.2013.0105","volume":"24","author":"RL Findling","year":"2014","unstructured":"Findling RL, Pathak S, Earley WR, Liu S, DelBello MP. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8\u00a0week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2014;24(6):325\u201335.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"10","key":"439_CR6","first-page":"1","volume":"75","author":"K Gao","year":"2014","unstructured":"Gao K, Wu R, Kemp DE, Chen J, Karberg E, Conroy C, Chan P, Ren M, Serrano MB, Ganocy SJ. Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial. J Clin Psychiatry. 2014;75(10):1\u2013478.","journal-title":"J Clin Psychiatry."},{"issue":"2","key":"439_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1176\/appi.ajp.2010.10091292","volume":"168","author":"MI Naharci","year":"2011","unstructured":"Naharci MI, Karadurmus N, Demir O, Bozoglu E, Ak M, Doruk H. Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine. Am J Psychiatry. 2011;168(2):212.","journal-title":"Am J Psychiatry."},{"issue":"5","key":"439_CR8","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/01.jcp.0000236654.85791.ae","volume":"26","author":"MA Rettenbacher","year":"2006","unstructured":"Rettenbacher MA, Baumgartner S, Eder-Ischia U, Edlinger M, Graziadei I, Hofer A, Huber R, Hummer M, Kemmler G, Weiss E, Fleischhacker WW. Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study. J Clin Psychopharmacol. 2006;26(5):500\u20133.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"439_CR9","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/00042737-200412000-00029","volume":"16","author":"I El Hajj","year":"2004","unstructured":"El Hajj I, Sharara AI, Rockey DC. Subfulminant liver failure associated with quetiapine. Eur J Gastroenterol Hepatol. 2004;16(12):1415\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"15","key":"439_CR10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/archinte.159.15.1681","volume":"159","author":"MC Reid","year":"1999","unstructured":"Reid MC, Fiellin DA, O\u2019Connor PG. Hazardous and harmful alcohol consumption in primary care. Arch Intern Med. 1999;159(15):1681\u20139.","journal-title":"Arch Intern Med"},{"issue":"12","key":"439_CR11","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1001\/archpsyc.59.12.1125","volume":"59","author":"Q Fu","year":"2002","unstructured":"Fu Q, Heath AC, Bucholz KK, Nelson E, Goldberg J, Lyons MJ, True WR, Jacob T, Tsuang MT, Eisen SA. Shared genetic risk of major depression, alcohol dependence, and marijuana dependence: contribution of antisocial personality disorder in men. Arch Gen Psychiatry. 2002;59(12):1125\u201332.","journal-title":"Arch Gen Psychiatry"},{"issue":"19","key":"439_CR12","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","volume":"264","author":"DA Regier","year":"1990","unstructured":"Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;264(19):2511\u20138.","journal-title":"JAMA"},{"issue":"2","key":"439_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/mpr.166","volume":"13","author":"RC Kessler","year":"2004","unstructured":"Kessler RC, Merikangas KR. The National Comorbidity Survey Replication (NCS-R): background and aims. Int J Methods Psychiatr Res. 2004;13(2):60\u20138.","journal-title":"Int J Methods Psychiatr Res."},{"issue":"2","key":"439_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0920-9964(02)00523-6","volume":"67","author":"HC Margolese","year":"2004","unstructured":"Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res. 2004;67(2):157\u201366.","journal-title":"Schizophr Res"},{"issue":"5","key":"439_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.0963-7214.2004.00309.x","volume":"13","author":"KT Brady","year":"2004","unstructured":"Brady KT, Back SE, Coffey SF. Substance abuse and posttraumatic stress disorder. Curr Dir Psychol Sci. 2004;13(5):206\u20139.","journal-title":"Curr Dir Psychol Sci"},{"issue":"4","key":"439_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/JCP.0b013e3180ca86e5","volume":"27","author":"KM Kampman","year":"2007","unstructured":"Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C, Tirado C, Oslin DW, Sparkman T, O\u2019Brien CP. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol. 2007;27(4):344.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"439_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/hup.944","volume":"23","author":"GI Martinotti","year":"2008","unstructured":"Martinotti GI, Andreoli S, Di Nicola MA, Di Giannantonio M, Sarchiapone M, Janiri L. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Human Psychopharmacol Clin Experim. 2008;23(5):417\u201324.","journal-title":"Human Psychopharmacol Clin Experim."},{"issue":"7","key":"439_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","volume":"40","author":"CL DeVane","year":"2001","unstructured":"DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine. Clin Pharmacokinet. 2001;40(7):509\u201322.","journal-title":"Clin Pharmacokinet"},{"key":"439_CR19","unstructured":"Food and Drug Administration [Internet]. Silver Spring (MD). Medication Guide Seroquel; 2013 [cited 2013, October]."},{"issue":"10","key":"439_CR20","doi-asserted-by":"publisher","first-page":"742","DOI":"10.4088\/JCP.v61n1006","volume":"61","author":"KI Melkersson","year":"2000","unstructured":"Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61(10):742\u20139.","journal-title":"J Clin Psychiatry"},{"key":"439_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/NDT.S50248","volume":"10","author":"G Wang","year":"2014","unstructured":"Wang G, McIntyre A, Earley WR, Raines SR, Eriksson H. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:201.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"16","key":"439_CR22","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221\u201331.","journal-title":"N Engl J Med"},{"issue":"12","key":"439_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.v59n1208c","volume":"59","author":"MK Fertig","year":"1998","unstructured":"Fertig MK, Brooks VG, English CW. Hyperglycemia associated with olanzapine. J Clin Psychiatry. 1998;59(12):1\u2013478.","journal-title":"J Clin Psychiatry."},{"issue":"4","key":"439_CR24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1176\/appi.ajp.2008.08020189","volume":"166","author":"T Suppes","year":"2009","unstructured":"Suppes T, Vieta E, Liu S, Brecher M, Paulsson B, Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry. 2009;166(4):476\u201388.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"439_CR25","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","volume":"40","author":"CL DeVane","year":"2001","unstructured":"DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine. Clin Pharmacokinet. 2001;40(7):509\u201322.","journal-title":"Clin Pharmacokinet"},{"key":"439_CR26","unstructured":"AstraZeneca [Internet]. Wilmington (DE). Prescribing information for SEROQUEL XR including Boxed Warnings; 2013 [cited 2013, October]."},{"issue":"8","key":"439_CR27","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/S0149-2918(03)80220-5","volume":"25","author":"PS Masand","year":"2003","unstructured":"Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003;25(8):2289\u2013304.","journal-title":"Clin Ther"},{"issue":"3","key":"439_CR28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1530-0277.2011.01649.x","volume":"36","author":"RZ Litten","year":"2012","unstructured":"Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H. A, Double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012;36(3):406\u201316.","journal-title":"Alcohol Clin Exp Res"},{"issue":"10","key":"439_CR29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.biopsych.2004.07.016","volume":"56","author":"HM Pettinati","year":"2004","unstructured":"Pettinati HM. Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry. 2004;56(10):785\u201392.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"439_CR30","first-page":"1105","volume":"71","author":"PT Giboney","year":"2005","unstructured":"Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Phys. 2005;71(6):1105.","journal-title":"Am Fam Phys"},{"issue":"10","key":"439_CR31","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1097\/01.ALC.0000091227.26627.75","volume":"27","author":"LC Sobell","year":"2003","unstructured":"Sobell LC, Sobell MB, Connors GJ, Agrawal S. Assessing drinking outcomes in alcohol treatment efficacy studies: selecting a yardstick of success. Alcohol Clin Exp Res. 2003;27(10):1661\u20136.","journal-title":"Alcohol Clin Exp Res"},{"issue":"12","key":"439_CR32","doi-asserted-by":"publisher","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","volume":"137","author":"G Ostapowicz","year":"2002","unstructured":"Ostapowicz G, Fontana RJ, Schi\u00f8dt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947\u201354.","journal-title":"Ann Intern Med"},{"issue":"2","key":"439_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/jhep.2002.34857","volume":"36","author":"C Sgro","year":"2002","unstructured":"Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451\u20135.","journal-title":"Hepatology"},{"issue":"7","key":"439_CR34","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2165\/00002018-200124070-00001","volume":"24","author":"N Kaplowitz","year":"2001","unstructured":"Kaplowitz N. Drug-induced liver disorders. Drug Saf. 2001;24(7):483\u201390.","journal-title":"Drug Saf"},{"issue":"3","key":"439_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/hup.833","volume":"22","author":"G Martinotti","year":"2007","unstructured":"Martinotti G, Di Nicola M, Romanelli R, Andreoli S, Pozzi G, Moroni N, Janiri L. High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. Human Psychopharmacol Clin Experim. 2007;22(3):149\u201356.","journal-title":"Human Psychopharmacol Clin Experim."},{"issue":"3","key":"439_CR36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/alcalc\/agr017","volume":"46","author":"G Addolorato","year":"2011","unstructured":"Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, Gasbarrini G, Landolfi R. Dose\u2013response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2011;46(3):312\u20137.","journal-title":"Alcohol Alcohol"},{"issue":"1","key":"439_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12328-016-0626-y","volume":"9","author":"Y Suzuki","year":"2016","unstructured":"Suzuki Y, Yamazaki Y, Hashizume H, Kobayashi T, Ohyama T, Horiguchi N, Sato K, Kakizaki S, Kusano M, Yamada M. Endoscopic treatment for esophageal varices complicated by Isaacs\u2019 syndrome involving difficulty with conventional sedation. Clin J Gastroenterol. 2016;9(1):27\u201331.","journal-title":"Clin J Gastroenterol"},{"issue":"6","key":"439_CR38","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1345\/aph.1Q032","volume":"45","author":"JM Sendra","year":"2011","unstructured":"Sendra JM, Junyent TT, Pellicer MJ. Pregabalin-induced hepatotoxicity. Ann Pharmacother. 2011;45(6):e32.","journal-title":"Ann Pharmacother"},{"key":"439_CR39","unstructured":"Addolorato G, Mirijello A, Barrio P, Gual A. Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol. 2016; pii: S0168-8278(16)30181-7."},{"issue":"1","key":"439_CR40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1124\/jpet.113.207621","volume":"347","author":"RH Schmidt","year":"2013","unstructured":"Schmidt RH, Jokinen JD, Massey VL, Falkner KC, Shi X, Yin X, Zhang X, Beier JI, Arteel GE. Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs. J Pharmacol Exp Ther. 2013;347(1):126\u201335.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"439_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1475-2832-3-7","volume":"3","author":"KD McLaren","year":"2004","unstructured":"McLaren KD, Marangell LB. Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities. Ann Gen Psychiatry. 2004;3(1):7.","journal-title":"Ann Gen Psychiatry."},{"issue":"10","key":"439_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.v63n1002","volume":"63","author":"DA Wirshing","year":"2002","unstructured":"Wirshing DA, Boyd JA, Meng LR, Ballon JS, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63(10):1\u2013478.","journal-title":"J Clin Psychiatry."},{"issue":"6","key":"439_CR43","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.pnpbp.2007.05.005","volume":"31","author":"N Atasoy","year":"2007","unstructured":"Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, Ustundag Y. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1255\u201360.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"439_CR44","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMra021844","volume":"349","author":"WM Lee","year":"2003","unstructured":"Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349(5):474\u201385.","journal-title":"N Engl J Med"},{"issue":"1","key":"439_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/BF02245249","volume":"118","author":"M Kurz","year":"1995","unstructured":"Kurz M, Hummer M, Oberbauer H, Fleischhacker WW. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology. 1995;118(1):52\u20136.","journal-title":"Psychopharmacology"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0439-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0439-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0439-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T22:51:21Z","timestamp":1589669481000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0439-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["439"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0439-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2016,8,8]]},"assertion":[{"value":"8 August 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by the NIH - National Institute of Alcohol Abuse and Alcoholism: CSP-1027 (VV) and Z99-AA999999 (VV); P50-AA024337-01, U01-AA021901 and R37-AA010762 (CJM); and ZIA AA000466 (VAR).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Vatsalya Vatsalya, Akash Pandey, Melanie L. Schwandt, Shirish S. Barve, Matthew C. Cave, Vijay A. Ramchandani, and Craig J. McClain declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration\/Conflict of interest"}},{"value":"All procedures in this study were in accordance with the 1964 Helsinki Declaration (and its amendments).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This study was approved by the IRB of specific sites that recruited patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Committee"}},{"value":"All study patients enrolled in this study consented to participate in this treatment study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"This article is a US Government-sponsored work and is in the public domain in the USA.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"NIH and Public Access Policy"}}]}}